A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05192486
- Locations
- 🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
🇨🇳Affiliated Hospital of Hebei University, Baoding, Hebei, China
🇨🇳The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 29
- Registration Number
- NCT05160545
- Locations
- 🇨🇳
West China Hospital，Sichuan University, Chengdu, Sichuan, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Dongguan People's Hospital, Dongguan, Guangdong, China
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT05104775
- Locations
- 🇨🇳
The Second People's Hospital of Yibin, Yibin, Sichuang, China
🇨🇳Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC
- Conditions
- Interventions
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05054439
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China
🇨🇳The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05044897
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China
🇨🇳The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳Shanghai Oriental Hospital, Shanghai, Shanghai, China
SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT05039944
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Registration Number
- NCT05039931
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Sichuan, Sichuan, China
SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.
- Conditions
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05022654
- Locations
- 🇨🇳
Anyang Cancer Hospital of Henan Province, Anyang, Henan, China
🇨🇳Suining Central Hospital, Suining, Sichuan, China
🇨🇳Xuzhou Central Hospital, Xuzhou, Jiangsu, China
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05020457
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong, China
🇨🇳The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05020769
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China
🇨🇳The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center (SYSUCC), Guangdong, Guangzhou, China